China National Medicines Corporation Ltd.

Informe acción SHSE:600511

Capitalización de mercado: CN¥25.9b

China National Medicines Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Guotao Tian

Chief Executive Officer (CEO)

CN¥2.6m

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO2.5yrs
Participación del CEOn/a
Permanencia media de la dirección1.9yrs
Promedio de permanencia en la Junta Directiva2.6yrs

Actualizaciones recientes de la dirección

Recent updates

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

Nov 12
We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26
China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28
Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24
China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07
China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05
Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10
Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28
China National Medicines (SHSE:600511) Could Easily Take On More Debt

CEO

Guotao Tian (53 yo)

2.5yrs

Permanencia

CN¥2,550,000

Compensación

Mr. Guotao Tian is GM & Director of China National Medicines Corporation Ltd. from April 07, 2022.


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Guotao Tian
GM & Director2.5yrsCN¥2.55msin datos
Fei Chen
Chief Financial Officer1.1yrsCN¥191.30ksin datos
Lichun Luo
Board Secretary2.5yrsCN¥1.15msin datos
Zhang Ting
Deputy Secretary of the Party Committeeno dataCN¥371.90ksin datos

1.9yrs

Permanencia media

46yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600511 no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Guotao Tian
GM & Director2.6yrsCN¥2.55msin datos
Xiuchang Jiang
Chairman13.7yrssin datossin datos
Yong Liu
Director12.9yrssin datossin datos
Jingyun Liu
Chairman of the Supervisory Board12.9yrssin datossin datos
Luwen Shi
Independent Director2.6yrsCN¥200.00ksin datos
Xingxi Yu
Independent Director2.6yrsCN¥200.00ksin datos
Deyong Wen
Director5.5yrssin datossin datos
Xin Jiang
Director2.6yrsCN¥2.55msin datos
Xiaojuan Li
Director2.6yrssin datossin datos
Kai Lu
Supervisor2.6yrssin datossin datos

2.6yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 600511 no se considera experimentada (2.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.